Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 9/20 | 0.57 |
| ▸ | WNT3A | P56704 | 9/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.49 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9348517 | 0.92 | HDAC8 (0.59) | CTNNB1WNT3AABCB1HDAC8HDAC1 | |
| SCHEMBL15979734 | 0.87 | CTNNB1 (0.71) | CTNNB1WNT3AHDAC8HDAC1NPC1 | |
| SCHEMBL954173 | 0.86 | NPC1 (0.62) | CTNNB1WNT3AABCB1HDAC8HDAC1 | |
| SCHEMBL30218361 | 0.86 | NPC1 (0.62) | CTNNB1WNT3AABCB1HDAC8HDAC1 | |
| SCHEMBL26644901 | 0.85 | CTNNB1 (0.66) | CTNNB1WNT3AHDAC8HDAC1NPC1 | |
| SCHEMBL31686110 | 0.85 | CTNNB1 (0.66) | CTNNB1WNT3AHDAC8HDAC1NPC1 | |
| SCHEMBL14925418 | 0.85 | IDO1 (0.48) | CTNNB1WNT3ANPC1KMT2AALDH1A1 | |
| SCHEMBL10834673 | 0.83 | KDM4E (0.54) | CTNNB1WNT3AKMT2AALDH1A1HTT | |
| SCHEMBL3949459 | 0.82 | CTNNB1 (0.54) | CTNNB1WNT3AABCB1NPC1KMT2A | |
| SCHEMBL5307918 | 0.82 | CTNNB1 (0.61) | CTNNB1WNT3AHDAC8HDAC1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777015-B2 | Useful thiophene derivatives in the treatment of diabetes | METABRAIN RESEARCH (FR) | 2017-10-03 | — | — | US | disclosed |
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | METABRAIN RESEARCH (FR) | 2015-07-16 | — | — | US | disclosed |
| US-8865707-B2 | Cholesteryl ester transfer protein inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-21 | — | — | US | disclosed |
| EP-1973546-B1 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20090018054-A1 | Cholesteryl Ester Transfer Protein Inhibitors | MERCK SHARP & DOHME LLC | 2009-01-15 | — | — | US | disclosed |
| EP-1973546-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | Merck & Co., Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007081570-A2 | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-5292768-A | Compound effective as cerebral insufficiency improver | SUNTORY LIMITED (JP) | 1994-03-08 | — | — | US | disclosed |
| US-5288752-A | Brain disorders | SUNTORY LIMITED (JP) | 1994-02-22 | — | — | US | disclosed |
| EP-0322248-B1 | COMPOUNDS EFFECTIVE AGAINST CEREBRAL INSUFFICIENCY | SUNTORY LIMITED (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5179092-A | Cognition activators | SUNTORY LIMITED (JP) | 1993-01-12 | — | — | US | disclosed |
| US-5057514-A | Compounds effective as cerebral schemia treating agents | SUNTORY LIMITED (JP) | 1991-10-15 | — | — | US | disclosed |
| EP-0322248-A2 | Compounds effective against cerebral insufficiency | SUNTORY LIMITED (JP) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197530-A1 | USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES | SLC5A2, SLC5A1, TPMT | CTNNB1 1159/4885WNT3A 2277/4885ABCB1 366/4885 |
| US-20090018054-A1 | Cholesteryl Ester Transfer Protein Inhibitors | CETP, APOB, MTTP | CTNNB1 1467/4885WNT3A 1779/4885ABCB1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.